Literature DB >> 18414480

Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle.

DeWayne Townsend1, Soichiro Yasuda, Sheng Li, Jeffrey S Chamberlain, Joseph M Metzger.   

Abstract

Duchenne muscular dystrophy (DMD) is a fatal disease characterized by deterioration of striated muscle, affecting skeletal and cardiac muscles. Recently, several therapeutic approaches have shown promise for repairing dystrophic skeletal muscles. However, these methods often leave the dystrophic heart untreated. Here we show that, in comparison to fully dystrophin-deficient animals, targeted transgenic repair of skeletal muscle, but not cardiac muscle, in otherwise dystrophin-deficient (mdx) mice paradoxically elicited a fivefold increase in cardiac injury and dilated cardiomyopathy in these animals in vivo. Skeletal muscle repair was shown to increase the voluntary activity of the mdx mice as quantified by voluntary running on the exercise wheel. Because the dystrophin-deficient heart is highly sensitive to increased stress, we hypothesize that increased activity (enabled by the repaired skeletal muscle) provided the stimulus for heightened cardiac injury and heart remodeling. In support of this hypothesis, the primary cellular compliance defect in dystrophin-deficient cardiac myocytes was found to be unchanged by skeletal muscle repair in the mdx mice. These findings provide new information on the evolution of cardiac disease in dystrophin-deficient animals and underscore the importance of implementing global striated muscle therapies for muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18414480      PMCID: PMC2592846          DOI: 10.1038/mt.2008.52

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

1.  A novel Alu-like element rearranged in the dystrophin gene causes a splicing mutation in a family with X-linked dilated cardiomyopathy.

Authors:  A Ferlini; N Galié; L Merlini; C Sewry; A Branzi; F Muntoni
Journal:  Am J Hum Genet       Date:  1998-08       Impact factor: 11.025

2.  Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy.

Authors:  R Ortiz-Lopez; H Li; J Su; V Goytia; J A Towbin
Journal:  Circulation       Date:  1997-05-20       Impact factor: 29.690

3.  X-linked dilated cardiomyopathy.

Authors:  B A Berko; M Swift
Journal:  N Engl J Med       Date:  1987-05-07       Impact factor: 91.245

4.  Echocardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies.

Authors:  C Kirchmann; D Kececioglu; R Korinthenberg; S Dittrich
Journal:  Pediatr Cardiol       Date:  2005 Jan-Feb       Impact factor: 1.655

5.  Dystrophin gene abnormalities in two patients with idiopathic dilated cardiomyopathy.

Authors:  F Muntoni; A Di Lenarda; M Porcu; G Sinagra; A Mateddu; G Marrosu; A Ferlini; M Cau; J Milasin; M A Melis; M G Marrosu; C Cianchetti; A Sanna; A Falaschi; F Camerini; M Giacca; L Mestroni
Journal:  Heart       Date:  1997-12       Impact factor: 5.994

Review 6.  X-linked dilated cardiomyopathy and the dystrophin gene.

Authors:  A Ferlini; C Sewry; M A Melis; A Mateddu; F Muntoni
Journal:  Neuromuscul Disord       Date:  1999-07       Impact factor: 4.296

7.  Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles.

Authors:  Qi Long Lu; Adam Rabinowitz; Yun Chao Chen; Toshifumi Yokota; HaiFang Yin; Julia Alter; Atif Jadoon; George Bou-Gharios; Terence Partridge
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-17       Impact factor: 11.205

8.  Sequential changes in cardiac structure and function in patients with Duchenne type muscular dystrophy: a two-dimensional echocardiographic study.

Authors:  K Sasaki; K Sakata; E Kachi; S Hirata; T Ishihara; K Ishikawa
Journal:  Am Heart J       Date:  1998-06       Impact factor: 4.749

9.  X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus.

Authors:  J A Towbin; J F Hejtmancik; P Brink; B Gelb; X M Zhu; J S Chamberlain; E R McCabe; M Swift
Journal:  Circulation       Date:  1993-06       Impact factor: 29.690

10.  A point mutation in the 5' splice site of the dystrophin gene first intron responsible for X-linked dilated cardiomyopathy.

Authors:  J Milasin; F Muntoni; G M Severini; L Bartoloni; M Vatta; M Krajinovic; A Mateddu; C Angelini; F Camerini; A Falaschi; L Mestroni; M Giacca
Journal:  Hum Mol Genet       Date:  1996-01       Impact factor: 6.150

View more
  55 in total

1.  Delta-sarcoglycan gene therapy halts progression of cardiac dysfunction, improves respiratory failure, and prolongs life in myopathic hamsters.

Authors:  Masahiko Hoshijima; Takeharu Hayashi; Young E Jeon; Zhenxing Fu; Yusu Gu; Nancy D Dalton; Mark H Ellisman; Xiao Xiao; Frank L Powell; John Ross
Journal:  Circ Heart Fail       Date:  2010-10-29       Impact factor: 8.790

2.  DOT1L regulates dystrophin expression and is critical for cardiac function.

Authors:  Anh T Nguyen; Bin Xiao; Ronald L Neppl; Eric M Kallin; Juan Li; Taiping Chen; Da-Zhi Wang; Xiao Xiao; Yi Zhang
Journal:  Genes Dev       Date:  2011-02-01       Impact factor: 11.361

Review 3.  Progress in gene therapy of dystrophic heart disease.

Authors:  Y Lai; D Duan
Journal:  Gene Ther       Date:  2012-02-09       Impact factor: 5.250

4.  Measuring Pressure Volume Loops in the Mouse.

Authors:  DeWayne Townsend
Journal:  J Vis Exp       Date:  2016-05-02       Impact factor: 1.355

5.  Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.

Authors:  Bo Wu; Hong M Moulton; Patrick L Iversen; Jiangang Jiang; Juan Li; Jianbin Li; Christopher F Spurney; Arpana Sali; Alfredo D Guerron; Kanneboyina Nagaraju; Timothy Doran; Peijuan Lu; Xiao Xiao; Qi Long Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-19       Impact factor: 11.205

6.  Early right ventricular fibrosis and reduction in biventricular cardiac reserve in the dystrophin-deficient mdx heart.

Authors:  Tatyana A Meyers; DeWayne Townsend
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-12-05       Impact factor: 4.733

7.  Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Authors:  Nalinda B Wasala; Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

8.  Mesodermal iPSC-derived progenitor cells functionally regenerate cardiac and skeletal muscle.

Authors:  Mattia Quattrocelli; Melissa Swinnen; Giorgia Giacomazzi; Jordi Camps; Ines Barthélemy; Gabriele Ceccarelli; Ellen Caluwé; Hanne Grosemans; Lieven Thorrez; Gloria Pelizzo; Manja Muijtjens; Catherine M Verfaillie; Stephane Blot; Stefan Janssens; Maurilio Sampaolesi
Journal:  J Clin Invest       Date:  2015-11-16       Impact factor: 14.808

9.  CRABP1 protects the heart from isoproterenol-induced acute and chronic remodeling.

Authors:  Sung Wook Park; Shawna D Persaud; Stanislas Ogokeh; Tatyana A Meyers; DeWayne Townsend; Li-Na Wei
Journal:  J Endocrinol       Date:  2018-01-25       Impact factor: 4.286

Review 10.  Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics.

Authors:  Abdallah Fayssoil; Olivier Nardi; David Orlikowski; Djillali Annane
Journal:  Heart Fail Rev       Date:  2010-01       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.